Literature DB >> 19589593

JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia.

Leonardo Campiotti, Lorena Appio, Francesco Solbiati, Walter Ageno, Achille Venco.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19589593     DOI： 10.1016/j.leukres.2009.06.011

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  9 in total

1.  JAK2 V617F mutation positive primary myelofibrosis with concomitant t(9;11;22)(q34;p15;q11.2) but no BCR/ABL fusion.

Authors:  Wing-Yan Au; Thomas S K Wan; Edmond S K Ma
Journal:  Int J Hematol       Date:  2013-02-07       Impact factor: 2.490

2.  Coexistence of JAK2V617F Mutation and BCR-ABL Translocation in a Pregnant Woman with Essential Thrombocythemia.

Authors:  You-Wen Qin; Yi-Ning Yang; Su Li; Chun Wang
Journal:  Indian J Hematol Blood Transfus       Date:  2014-04-11       Impact factor: 0.900

3.  Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.

Authors:  Craig R Soderquist; Mark D Ewalt; David R Czuchlewski; Julia T Geyer; Heesun J Rogers; Eric D Hsi; Sa A Wang; Carlos E Bueso-Ramos; Attilio Orazi; Daniel A Arber; Elizabeth O Hexner; Daria V Babushok; Adam Bagg
Journal:  Mod Pathol       Date:  2018-01-12       Impact factor: 7.842

4.  Chronic myeloid leukemia patient with co-occurrence of BCR-ABL junction and JAK2 V617F mutation.

Authors:  Weiyi Xu; Baode Chen; Xiangmin Tong
Journal:  Int J Hematol       Date:  2013-11-30       Impact factor: 2.490

5.  Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm.

Authors:  Abdulaziz Hassan; Livingstone Gayus Dogara; Ahmadu Aliyu Babadoko; Sani Awwalu; Aisha Indo Mamman
Journal:  Niger Med J       Date:  2015 Jan-Feb

6.  Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib.

Authors:  A Zhou; E M Knoche; E K Engle; D A C Fisher; S T Oh
Journal:  Blood Cancer J       Date:  2015-10-02       Impact factor: 11.037

Review 7.  Concurrent JAK2-Positive Myeloproliferative Disorder and Chronic Myelogenous Leukemia: A Novel Entity? A Case Report With Review of the Literature.

Authors:  Gilbert Bader; Bernard Dreiling
Journal:  J Investig Med High Impact Case Rep       Date:  2019 Jan-Dec

8.  Emergence of BCR-ABL1 Chronic Myeloid Leukemia in a JAK2-V617F Polycythemia Vera.

Authors:  Mariana Lorenzo; Sofia Grille; Mariana Stevenazzi
Journal:  J Hematol       Date:  2020-04-23

9.  Two cases of myeloproliferative neoplasm with a concurrent JAK2 (V617F) mutation and BCR/ABL translocation without chronic myelogenous leukemia phenotype acquisition during hydroxyurea treatment.

Authors:  Sang Hyuk Park; Hyun-Sook Chi; Young-Uk Cho; Seongsoo Jang; Chan-Jeoung Park; Dae-Young Kim; Je-Hwan Lee; Kyoo-Hyung Lee
Journal:  Ann Lab Med       Date:  2013-04-17       Impact factor: 3.464
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.